These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12626459)

  • 1. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.
    Chua PK; Melish ME; Yu Q; Yanagihara R; Yamamoto KS; Nerurkar VR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):308-14. PubMed ID: 12626459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions].
    Yang SW; Wang DW; Li J; Qin YM; Wang FM; Cao LM; Zhang LF; Hu Z
    Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease.
    Gavin PJ; Crawford SE; Shulman ST; Garcia FL; Rowley AH
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):576-81. PubMed ID: 12692003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis.
    Matsuyama T
    Pediatr Int; 1999 Jun; 41(3):239-45. PubMed ID: 10365570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.
    Senzaki H; Masutani S; Kobayashi J; Kobayashi T; Nakano H; Nagasaka H; Sasaki N; Asano H; Kyo S; Yokote Y
    Circulation; 2001 Aug; 104(8):860-3. PubMed ID: 11514369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease.
    Takeshita S; Tokutomi T; Kawase H; Nakatani K; Tsujimoto H; Kawamura Y; Sekine I
    Clin Exp Immunol; 2001 Aug; 125(2):340-4. PubMed ID: 11529928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity.
    Ertugrul G; Keles D; Oktay G; Aktan S
    Arch Dermatol Res; 2018 Mar; 310(2):173-179. PubMed ID: 29349515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease.
    Sakata K; Hamaoka K; Ozawa S; Niboshi A; Yahata T; Fujii M; Hamaoka A; Toiyama K; Nishida M; Itoi T
    Circ J; 2010 Aug; 74(8):1670-5. PubMed ID: 20534943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of small interfering RNA on matrix metalloproteinase-9 expression in vascular endothelial cells stimulated by serum from children with Kawasaki disease].
    Chen ZH; Wan GP; Gu XQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Sep; 37(9):837-40. PubMed ID: 20128385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial differences of matrix metalloproteinase-2 and matrix metalloproteinase-9 within abdominal aortic aneurysm wall and intraluminal thrombus.
    Siennicka A; Zuchowski M; Kaczmarczyk M; Cnotliwy M; Clark JS; Jastrzebska M
    J Physiol Pharmacol; 2016 Dec; 67(6):903-910. PubMed ID: 28195071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression.
    Eagleton MJ; Peterson DA; Sullivan VV; Roelofs KJ; Ford JA; Stanley JC; Upchurch GR
    J Surg Res; 2002 May; 104(1):15-21. PubMed ID: 11971672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperoxia decreases matrix metalloproteinase-9 and increases tissue inhibitor of matrix metalloproteinase-1 protein in the newborn rat lung: association with arrested alveolarization.
    Hosford GE; Fang X; Olson DM
    Pediatr Res; 2004 Jul; 56(1):26-34. PubMed ID: 15128910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of intravenous immunoglobulin upon the overexpression and over-activation of nuclear factor-κB and matrix metalloproteinase-9 in murine model of Kawasaki disease].
    Shangguan W; Du Z; Yang H; Zhang Y; Song M; Dong W
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):938-43. PubMed ID: 24854917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
    Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
    Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
    Inoue N; Takai S; Jin D; Okumura K; Okamura N; Kajiura M; Yoshikawa S; Kawamura N; Tamai H; Miyazaki M
    Clin Chim Acta; 2010 Feb; 411(3-4):267-9. PubMed ID: 19945447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
    Chen R; Zhang AR; Zhao XX; Li ZH
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.